Tetra Bio-Pharma’s executive team, board of directors, and advisory committee are recognized experts in their respective fields including drug development, regulatory affairs, clinical research, intellectual property, marketing and medical affairs.
Together, the company’s leadership team provides an extensive background to support Tetra Bio-Pharma’s long-term vision to offer a diverse portfolio of cannabinoid-derived drugs to address unmet medical needs.
EXECUTIVE MANAGEMENT TEAM
Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, is a drug development specialist with 25 years experience in the pharmaceutical industry. Having obtained a Master’s of Science and Doctorate (PhD) degree in biomedical sciences, he has developed an expertise in drug safety and regulatory affairs while working in the pharmaceutical and biotechnology industries. He has specific expertise in the development of drug-device combination products, biologics, and botanical medicines.
Dr. Chamberland has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Regulatory Officer since October 15, 2018. He is responsible for the transformation of the biotechnology company into a pharmaceutical firm that discovers, develops and commercializes cannabinoid-based pharmaceuticals. The mandate began with a company of less than 10 employees and today has over 50 employees specialized in regulatory affairs, clinical research, manufacturing compliance, clinical trial product manufacturing, clinical operations and research and development. Dr. Chamberland oversees the scientific and regulatory requirements for drug and medical device approval (i.e., vaporizers) and strategic planning for corporate development.
Dr. Chamberland has become a thought leader in botanical medicine, publishing, lecturing and delivering continuing education workshops to health professionals on the use of plants for the treatment of pain, anxiety, insomnia, and wound healing. He is a Professor of Botanical Medicine and Principles of Clinical Research at the École d’Enseignement Supérieur de Naturopathie du Québec (EESNQ) and the French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM). He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, and Certified Herbalist and Master Herbalist diplomas from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture form McGill University, an M.Sc. in Veterinary Anatomy and Physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.
Dr. Chamberland is a pioneer in drug-device combination products. He developed and executed the regulatory strategy for two novel products and obtained marketing approval. In 2002, he was invited by the FDA to present at the FDA Public Hearing to regulate combination products. He spent 7-years as a member of the Scientific Advisory Committee of a Venture Capital fund and 6-years on a Health Canada Expert Committee. He was also employed by the Victhom Laboratory; Angiogene Inc.; CATO Research Ltd; and MDS Pharma, respectively.
Before joining Tetra Bio-Pharma, Mr. Boily served as Vice-President and Financial Officer at Acasti Pharma Inc., a dual-listed (TSX-V & Nasdaq) biopharmaceutical innovator focused on the research and development of prescription drugs using Omega-3 fatty acids derived from krill oil for treatment of hypertriglyceridemia. He raised C$50M to fund the Trilogy Phase 3 program and later set-up an “at-the-market” (or ATM) program for aggregate proceeds of up to US$ 30M with sales on Nasdaq. He also migrated financial reporting to US-Gaaps to become a fully compliant SEC registrant and filed a registration statement on Form S-3 with the SEC to register up to US$200 million of common shares, warrants and units.
Prior to Acasti, Mr. Boily served as a Director of Finance & Information Technology at Innovaderm Research Inc., a North American contract research organization (CRO) specialized in dermatology. Working closely with the President and founder, Mr. Boily undertook a vast financial, IT and growth mandate and increased revenues and profits over 25%.
Formerly, Mr. Boily was a Director of Finance at Teva Canada Innovation where he oversaw and reported on the financial conduct of all clinical R&D activities and managing branded product launches in the therapeutic areas of central nervous system (CNS), respiratory, oncology and pain care.
Mr. Boily holds a Bachelor’s of Science in Accounting from HEC Montreal and is a Quebec-Chartered Public Accountant (CPA).
Mr. Néron has more than three decades of experience in the pharmaceutical industry where challenging the reimbursement landscape factored prominently in his role, with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada. Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market-leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).
Mr. Néron holds a Bachelor’s degree in Business Administration (BBA) in Marketing from Université du Québec in Chicoutimi (QC).
Melanie Kelly is a Professor in Pharmacology and Ophtamology at Dalhousie University in Halifax with expertise in preclinical and clinical research design, novel drug development, medical cannabis and cannabinoid based drugs.
A respected research professional with a Doctor of Philosophy (PhD) focused on drug discovery and molecular pharmacology, Dr. Kelly has significant research experience in the field of G protein coupled receptors and endocannabinoid/cannabinoid signaling. She is considered to be an expert in the cannabinoid drug development space.
Her primary research expertise is pharmacology, specifically receptors and cell signaling pathways. Her work has examined pathways important to the survival of retinal ganglion cells in experimental models of glaucoma and has made us of gene mutations, to explore signaling pathways involved in retinal progenitor cell growth and development. Dr. Kelly’s current research addresses the pharmacology of the endocannabinoids and lipid signaling in the mammalian eye, with a specific focus on the regulation of intraocular pressure and interactions between glial cells and microvasculature in the regulation of retinal blood flow.
She is a member of the International Cannabis Research Society.
OPERATIONAL MANAGEMENT TEAM
Dr. De Pauw is responsible for clinical operations and relations with the medical community with a view to building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company. She also directs the Company’s public education initiatives to build and increase awareness about the benefits and adverse effects of cannabis-cased treatment.
Aurelia holds a master’s degree and PhD in Science from the Gembloux Agro-Bio Tech, University of Liege and the University of Namur, Belgium. She followed this with a five-year post-doctoral position in the field of stem cell therapy. After establishing her career in basic sciences and regenerative therapy, she progressed from the laboratory bench to the bedside where she gained an even deeper appreciation of the impact of research on patients and caregivers. Aurelia has extensive experience in numerous therapeutic categories including oncology, drug abuse, endocrinology, dermatology and cardiology.
Prior to joining Tetra Bio-Pharma Team, Dania worked as Director of Pharmacy at Canopy Growth Corporation where she led the Canadian strategy and tactical plans for Retail & Hospital Pharmacy including pharmacy education, business development, public affairs initiatives, key opinion leaders and key accounts management (2017-2020). Dania worked on the cannabis file at Shoppers Drug Mart (2015-2017) where she led and supported launch initiatives within the cannabis space including pharmacy education, strategy, marketing, and medical cannabis operationalization.
Dania assumed diversified leadership roles within the pharmaceutical industry, in sales management, marketing, and medical functions at companies including GlaxoSmithKline, Procter & Gamble Pharma, Roche and Eisai (1998-2015). She contributed to the growth and launch of several pharmaceutical products in varied therapeutic areas in the Middle East/North Africa (MENA) region and Canada.
Over the last five years, Dania has developed a unique skill set that includes cannabinoid education, commercialization, and business development within the cannabis space. She led the training of thousands of Canadian pharmacists on all aspects of cannabinoids. This experience combined with her interest in cannabinoid medicine and polypharmacy reduction was a key asset for joining Tetra.
Mrs. Scott holds a Bachelor of Science in Biology and a Bachelor of Science in Pharmacy, both from Lebanese American University in Lebanon.
Mr. Ofer Yifrach-Stav has extensive experience in the pharmaceutical and medical device industries where he worked with leading companies in North America, Europe and Asia. During this time, he successfully led the process to prepare these companies for Quality Assurance Audits by Health Canada, the U.S. Food and Drug Administration (FDA), the EU and the Israeli Ministry of Health. Over the years he developed expertise in production process validations and other areas of quality assurance. As part of Tetra Bio-Pharma’s Management Team, Ofer is responsible for the scale-up activities of our lead products and for ensuring our readiness for the submission of NDS/NDA. Ofer holds a master’s degree in Environmental Engineering, which he graduated with honours. He also holds a bachelor’s degree in Biotechnology Engineering from Ben-Gurion University of the Negev, in Israel.
BOARD OF DIRECTORS
Dr. W.M. (Bill) Cheliak was CEO of MedBiome, a Canadian based start-up focussed on developing therapeutics to modulate the function of the microbiome in specific disease conditoins. As well, he served as CEO of Panag Pharma, a Canadian based bio-technology company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation, prior to the acquisition of Panag by Tetra. He is also co-founder and Interim CEO to Chelation Partners, a private company developing a technology to enhance the efficacy of antibiotics. Dr. Cheliak has over 20 years of experience as an entrepreneur having helped establish companies in a wide variety of life science fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and clinical research organization services. He brings extensive deal making experience with the pharmaceutical industry. He currently serves as a Director for Solarvest (SVS). Dr. Cheliak was Vice Chair of the Government of Canada’s Networks Centres Excellence (NCE) Standing Selection Committee and Chair of the NCE Monitoring Committee until September 2018.
Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, has been Chief Scientific Officer & Regulatory Affairs of Tetra from June 2016 until April 2018 when he was appointed Chief Executive Officer. He is also Chief Regulatory Officer of Tetra since October 15, 2018 and previously joined Tetra as Chief Scientific Officer in April 2016. He has been Vice President of Regulatory Affairs & Product Development at Biotanika Health Group Inc. since March 2007. He served as Vice President of Clinical & Regulatory Affairs at Victhom Laboratory Inc. from 2005 to 2007. He developed a specialty in regulatory affairs (drugs, biologics, medical device, combination products, botanicals). He works closely with physicians and naturopathic physicians in these clinical areas. He spent 6 years as the Co-Chair and member of Health Canada’s Expert Advisory Committee for Veterinary Natural Health Products and Low Risk VHP. He was the Program Director of MDS Pharma Services.
Dr. Chamberland has over 7 years’ experience in the development of clinical research protocols for botanical medicines and the management of these clinical studies in the areas of anxiety, sleep, pain, depression, inflammation and wound healing. He has over 26 years’ experience in the development of new drugs in the pharmaceutical industry (Canada and USA). He was a member of the Investment Committee of Fonds Bionovation for 7 years. Since 2007, Dr. Chamberland developed an expertise in botanical medicine and gave lectures and continuing education workshops for health professionals (physicians, naturopathic physicians, chiropractors, etc) on the use of plants in the treatment of pain, anxiety, insomnia, wound healing etc. He got three patents (Patent granted on the synergy of phyto-ingredients and antifungal agents.). He is the Professor of Botanical Medicine and Principles of clinical research at the Ecole d’Enseignement Superieur de Naturopathie du Quebec (EESNQ) and French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM). He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, a Certified Herbalist from the Dominion College of Canada and a Master Herbalist diploma from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture from McGill University, an M.Sc. in Veterinary anatomy and physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal
Mr. Merton has over 20 years of financial and business experience, including 10 years as CFO for public companies involved in the capital markets. Following 12 years with Ernst & Young and KPMG, he transitioned from the audit stream into financial advisory work, as a Business Valuator, Forensic Accountant and Corporate Finance specialist. After leaving KPMG, Mr. Merton joined Atlas Tube Inc., as Vice-President, Special Projects. Since assisting in the sale of Atlas Tube, Mr. Merton became the CFO of Reko International Group Inc. In December 2014, Mr. Merton was elected by shareholders as a member of the inaugural Board of Directors of Aphria Inc. Approximately one year later, Mr. Merton resigned as a member of the Board and joined Aphria as its CFO. In this role, Mr. Merton is responsible for communication with all stakeholders and is a member of the executive management team responsible for the strategic direction of Aphria, as well as leading all acquisition discussions, budgeting, financing, financial reporting and internal controls. Mr. Merton is a Chartered Professional Accountant, a Chartered Accountant and is a Fellow of the Canadian Institute of Chartered Business Valuators (the “CICBV”).
Dr. Brent Norton holds his medical doctorate degree from McGill University, an MBA from Ivey Business School at Western University and was granted the ICD.D designation by the Institute of Corporate Directors following the completion of the Directors Education Program at the Rotman School of Business in Toronto. With over 25 years of experience in the life sciences industry, Dr. Norton has used his cross-functional knowledge to develop strategy, raise capital and build important relationships in the academic and business community. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Eli Lilly, L’Oreal, Parke Davis/Pfizer and others, and taken products through the FDA to global out-licensing with Johnson & Johnson. His contributions to five companies have allowed early investors the opportunity to crystallize investment gains of over $2.5B. Brent is currently a Venture Partner with Lumira Ventures and has recently been appointed as a member of the prestigious Association of Faculties of Medicine of Canada.
Dale Weil brings close to 35 years of business development experience, much of which was acquired while working at McKesson Canada, a diversified healthcare company and the largest pharmaceutical distributor in the country. At McKesson Canada, Ms. Weil held various leadership positions, most recently as Senior Advisor to the President. Ms. Weil holds a Bachelor’s degree in Marine Biology and a Master’s degree in Business Administration, both from McGill University. Additionally, Dale received the ICD.D designation from the Institute of Corporate Directors. The ICD.D designation represents a lifelong commitment to excellence in the boardroom, a desire to stay current, and to be a more effective director. In January 2020, Dale was appointed as the Executive Director of the West Island Palliative Care Centre, an initiative that she has been involved with since 2010.